Skip to main content
Top
Published in: Reactions Weekly 1/2022

01-08-2022 | Tyrosine Kinase Inhibitors | Case report

Bosutinib

Various toxicities and lack of efficacy following off-label use: 5 case reports

Published in: Reactions Weekly | Issue 1/2022

Login to get access

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literature
go back to reference Claudiani S, et al. A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. European Journal of Haematology 109: 90-99, No. 1, Jul 2022. Available from: URL: http://doi.org/10.1111/ejh.13775 Claudiani S, et al. A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. European Journal of Haematology 109: 90-99, No. 1, Jul 2022. Available from: URL: http://​doi.​org/​10.​1111/​ejh.​13775
Metadata
Title
Bosutinib
Various toxicities and lack of efficacy following off-label use: 5 case reports
Publication date
01-08-2022
Publisher
Springer International Publishing
Published in
Reactions Weekly / Issue 1/2022
Print ISSN: 0114-9954
Electronic ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-20568-6

Other articles of this Issue 1/2022

Reactions Weekly 1/2022 Go to the issue

Case report

Multiple drugs

Case report

Zoledronic-acid